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The identity of the cellular receptor(s) for visna virus, an ovine lentivirus, is currently unknown; however, previous studies
from our laboratory have identified membrane-associated proteins expressed selectively in susceptible cells which bind
visna virus. Moreover, a polyclonal antibody (2-23), raised against a 45-kDa visna virus binding protein, bound specifically to
the surface of susceptible cells in immunofluorescence assays and significantly reduced binding of visna virus to cells (S. E.
Crane et al., 1991, J. Virol., 65, 6137–6143). In this report we extend our studies of this antibody (2-23), showing both that 2-23
significantly reduces visna virus infection of susceptible cells and that 2-23 immunoprecipitates a putative protein complex
consisting of a prominent 30-kDa protein, as well as the 45-kDa immunogen, specifically from radiolabeled virus-susceptible
sheep cells. Further, we demonstrate that the 30-kDa protein is a membrane-associated proteoglycan substituted with a
chondroitin sulfate glycosaminoglycan (GAG) chain(s) and that treatment of susceptible cells with an inhibitor of GAG
synthesis significantly reduces visna virus production. Collectively, these data support a role for a proteoglycan in visna virus
cell binding and infection. © 2000 Academic Press
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Visna virus is a member of the lentivirus family of
nononcogenic retroviruses, which includes human im-
munodeficiency virus (HIV), simian immunodeficiency vi-
rus (SIV), feline immunodeficiency virus (FIV), bovine
immunodeficiency virus, equine infectious anemia virus
(EIAV), caprine arthritic–encephalitis virus (CAEV), and
visna-maedi virus (visna virus), which infects sheep. Len-
tiviruses cause persistent infections and chronic pro-
gressive disease after prolonged incubation times in
their hosts, which culminate in multiorgan pathology with
an invariably fatal outcome. Differences in cellular
tropism and the development of clinically distinct dis-
eases divide the lentiviruses into two groups. HIV, SIV,
and FIV replicate in both lymphocytes and macrophages,
causing acquired immunodeficiency syndrome and or-
gan-specific diseases in the lung, central nervous sys-
tem (CNS), and gastrointestinal tract. In contrast, EIAV,
CAEV, and visna virus replicate predominately in macro-
phages, do not infect lymphocytes, and cause only or-
gan-specific disease of the CNS, lung, and joints (Clem-
ents and Zink, 1996).
Retroviruses have a common mechanism of entry that
involves binding to a specific cell surface receptor fol-
lowed by fusion of the viral envelope with the cell mem-
brane. Membrane proteins with multiple transmembrane
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132domains serve as receptors for a number of the retrovi-
ruses. The murine leukemia viruses (MLV-E) use a mul-
tiple membrane-spanning protein transporter of basic
amino acids (CAT-1) as a receptor (Kim et al., 1991; Wang
et al., 1991). A sodium-dependent neutral amino acid
transporter serves as the receptor for feline and baboon
endogenous retroviruses and for simian type D retrovi-
ruses (Tailor et al., 1999). A protein resembling a phos-
phate transporter (GLVR-1) serves as a receptor for both
gibbon ape leukemia virus and feline leukemia virus
subgroup B (Weiss and Tailor, 1995), and the chemokine
receptor CXCR4 serves as a receptor for FIV (Willett et
al., 1997). Although a majority of retroviruses require a
single cellular receptor protein for entry, HIV and SIV
utilize both CD4 and chemokine receptors (Broder and
Collman, 1997; Broder and Dimitrov, 1996). CD4 is re-
quired, but not sufficient, for entry of most strains of HIV
and SIV (Maddon et al., 1986). In contrast, the chemokine
receptors are always required and are, in some cases,
sufficient for entry of these viruses (Edinger et al., 1997;
Endres et al., 1996; Marcon et al., 1997; Reeves et al.,
997).
Currently, little is known about the receptors for the
ngulate lentiviruses, visna virus and CAEV; however,
wo candidate receptors have been proposed for the
isna virus receptor. Major histocompatibility complex
lass II antigen was previously implicated as a candidate
eceptor in that purified soluble ovine MHC Class II
revented virus binding to a 30-kDa protein on suscep-ible cells (Dalziel et al., 1991). However, the identity of
this 30-kDa protein was never confirmed to be MHCII
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133VISNA VIRUS MEMBRANE-ASSOCIATED PROTEIN(Dalziel et al., 1991). Experiments in our laboratory using
a virus overlay protein blot assay (VOPBA) identified
three membrane proteins able to bind visna virus, a 45-,
a 30-, and a 15-kDa protein (Crane et al., 1991). Polyclonal
antisera were raised to each of these proteins, and the
antiserum (2-23) raised against the 45-kDa protein bound
to susceptible cell surfaces by immunofluorescence, re-
acted with a 45-kDa protein as well as a 30-kDa protein
on sheep choroid plexus (SCP) membranes in Western
analyses, and diminished binding of radio-labeled virus
to SCP cells. Polyclonal antiserum against the 15-kDa
protein (2-21) labeled susceptible cells by immunofluo-
rescence, but did not inhibit virus binding to the surface
of cells; serum against the 30-kDa protein was nonreac-
tive. Collectively, these results suggested that a protein
complex might be involved in visna virus interaction with
the cell and that the 45-kDa protein is an important
component in this complex binding of visna virus to the
cell (Crane et al., 1991).
In this report, 2-23 was used to further characterize
cell surface proteins that mediate visna virus infection.
We have shown that 2-23 significantly reduced visna
virus infection of susceptible cells. Further, using lysis
conditions that favor the solubilization of integral mem-
brane proteins, we have shown that 2-23 immunoprecipi-
tates a complex of cellular proteins with apparent mo-
lecular weights of 30 and 45 kDa from lysates of cells
labeled with [14C]amino acids and cells labeled with
ran35S-Label. Because the 30-kDa protein was the
rominent protein in both 14C-labeled and 35S-labeled
ysates, we focused subsequent analyses on this protein
nd demonstrated that the 30-kDa protein is membrane
ssociated and is substituted with a chondroitin sulfate
lycosaminoglycan chain (GAG). Further, inhibition of
AG additions to proteoglycans, using a b-D-xyloside in
visna virus-susceptible cells, significantly reduced infec-
tion by visna virus. Collectively, the results presented
here, both dependent on and independent of the 2-23
antiserum, highlight the importance of a chondroitin sul-
fate proteoglycan in visna virus cell surface interactions
and infection.
RESULTS
Visna virus infection is inhibited by 2-23 antiserum
In a previous study, polyclonal antiserum was raised
against a 45-kDa protein that was shown to bind visna
virus in a VOPBA (Crane et al., 1991). This antiserum to
the 45-kDa protein (referred to as 2-23 throughout) rec-
ognized proteins on the surface of visna virus-suscepti-
ble cells by immunofluorescence, reduced virus-specific
binding to the surface of cells, and recognized the 45-
kDa immunogen and a 30-kDa membrane protein by
Western analysis (Crane et al., 1991).To extend the observation that 2-23 inhibited visna
virus binding to susceptible cells, we first evaluated the
d
fability of 2-23 to inhibit visna virus infection of SCP, a
primary cell susceptible to visna virus infection. SCP
cells were preincubated with IgG purified from the 2-23
serum, IgG purified from normal rabbit serum, commer-
cial normal rabbit IgG, or no antibody (virus control) at
4°C for 1 h. Incubations were done at 4°C to prevent
receptor internalization. Virus (100 TCID50) was added to
the cells at 4°C for 4 h, the cells were washed, and de
novo virus production was measured as described under
Materials and Methods. The 2-23 IgG reduced virus
production 100- to 550-fold compared to virus control and
rabbit IgG in three independent experiments (Table 1). In
contrast, the IgG from the normal rabbit serum reduced
the virus production only 10-fold, compared to the virus
control and rabbit IgG (Table 1). This latter result is not
surprising as it is well established in our laboratory that
serum components interfere with visna virus infection of
cells (J. E. Clements, personal communication). Appro-
priate control experiments were performed to ensure
that the 2-23 antiserum recognized a cellular protein and
not a viral protein. A standard neutralization assay was
modified such that 2-23 IgG, as well as IgG from normal
rabbit serum and visna-neutralizing antiserum (NN at a 1
to 50 dilution), was incubated with visna virus (100
TCID50) for 1 h at 37°C. The virus was separated from
ree antibody by centrifugation prior to being used for
nfection of SCP cells. The NN antiserum reduced the
nfectivity of the virus while the IgG from 2-23 and normal
abbit serum had no effect on virus titer. Thus, the 2-23
ntiserum does not reduce infectivity by binding to the
irus. In any event, it is clear that the 2-23 IgG signifi-
antly reduced virus infection when allowed to bind to
CP cells but not when incubated with the virus.
mmunoprecipitation of visna virus binding proteins
rom visna virus-susceptible cells
In order to study the membrane proteins recognized by
-23, cell lysis conditions were optimized to solubilize
ntegral membrane proteins. Nonionic and zwitterionic
TABLE 1
Fold Reduction in Virus Titer
Antibody Expt 1 Expt 2 Expt 3
2-23 IgG 550 100 100
NRS IgG 18 10 ND
Rabbit IgG 1.8 0 0
Note. Cells were infected with 100 TCID50 and virus titers were
determined by limiting dilution. The TCID50 was determined for the virus
ontrol and IgG-treated cells; the fold reduction was determined by
ividing the TCID50 of the virus control by the TCID50 obtained after
antibody treatment of cells. The NRS IgG treatment was not done (ND)
in Experiment 3.etergents have been shown repeatedly to be effective
or membrane protein extraction (Helenius and Simons,
e
v
i
i
3
B
i
v
F
l
S
t
(
v
(
134 BRUETT, BARBER, AND CLEMENTS1975). The 2-23 antiserum recognized specific cellular
proteins when cells were solubilized in zwitterionic or
nonionic detergents, such as CHAPS and n-octylglu-
coside, but not by ionic detergents such as SDS (data not
shown). Based on these observations, we lysed 14C-
labeled (most amino acids radiolabeled) SCP cells with a
CHAPS-based lysis buffer and used 2-23 for standard
immunoprecipitation. Normal rabbit serum was used as
the negative control in immunoprecipitations. SDS–PAGE
separation of 2-23 immunoprecipitates from SCP cells
identified two specific protein bands of ;30 and 45 kDa
(Fig. 1, lanes 11 and 12, asterisks). Of note, only these two
proteins were detected consistently in 2-23 immunopre-
cipitations, and the 30-kDa protein was always the most
prominent labeled band, in both 14C-labeled (Fig. 1) and
35S-labeled lysates (Fig. 3).
Consistent with classical receptor theory, we hypoth-
sized that if the 30- and 45-kDa proteins were integral to
irus binding/infection they would be expressed by most,
f not all, visna virus-susceptible cells. Hence we exam-
ned 2-23 immunoprecipitates from 14C-labeled cell ly-
sates of a number of visna virus-susceptible cells and
cell lines. In addition to SCP cells (Fig. 1, lane 11, aster-
isks), FLK-BLV (ovine embryonic kidney), MDOK (ovine
kidney), and GSM (goat synovial membrane) cells ex-
pressed both the 30- and the 45-kDa proteins (Fig. 1,
lanes 1, 3, and 5, asterisks). Immunoprecipitations with
2-23 from 14C-labeled nonsusceptible cell types, QT6
(quail fibrosarcoma cells) and NIH-3T3 (mouse embryo
FIG. 1. Immunoprecipitation of 14C-labeled cell lysates from visna
irus-susceptible and nonsusceptible cells with the 2-23 antiserum.
LK-BLV (ovine embryonic kidney, lanes 1 and 2), MDOK (ovine kidney,
anes 3 and 4), GSM (goat synovial membranes, lanes 5 and 6), and
CP (sheep choroid plexus, lanes 11 and 12) cells are each susceptible
o visna virus infection. QT6 (quail fibrosarcoma, lanes 7 and 8) and 3T3
mouse embryo fibroblast, lanes 9 and 10) cells are not susceptible to
isna virus infection. Immunoprecipitations from labeled cell lysates
100 mg) were done with 2-23 (1) or normal rabbit serum (2) as
described under Materials and Methods. Immunoprecipitated proteins
were separated on a 9% SDS–PAGE gel, detected by autoradiography,
and exposed to X-ray film. Asterisks indicate the specific proteins
consistently immunoprecipitated by the 2-23 antiserum from suscepti-
ble cells.fibroblast), did not contain either the 30-kDa protein or
the 45-kDa protein (Fig. 1, lanes 7 and 9).The 30-kDa protein is a membrane-associated protein
Classically, virus receptors are cellular membrane pro-
teins that bind the virus to the cell surface. Therefore, we
next examined 2-23 and normal rabbit serum (NRS) im-
munoprecipitations of proteins extracted from cellular
membranes of 14C/35S-labeled SCP cells. Our results
indicate that the 30-kDa protein was present in the mem-
brane (M) fraction (Fig. 2, lane 2). Compared to nonmem-
brane fractions of cellular lysates (Fig. 2, lanes 4 and 6)
we find that pelleted membranes contain amounts of the
30-kDa protein similar to those of the fractions of cy-
toskeletal aggregates (C) and that the 30-kDa protein is
not detectable in the homogenate fraction (H). These
results are consistent with a high turnover rate sug-
gested by the extensive incorporation of 35S or 14C in the
0-kDa protein.
iochemical characterization of the 30-kDa protein
Although the 30-kDa protein was readily detectable
n both 14C- (Fig. 1) and 35S-labeled lysates, it consis-
tently failed to stain with standard Coomassie blue,
Ponceau red, colloidal Coomassie, or silver stain.
Given this property of the protein, we considered the
possibilities that the concentration was below the
level of detection for these stains or that the protein is
glycosylated. Anionic glycoproteins may not stain with
these standard methods; in fact, some glycoproteins
are seen as negative bands in a silver stain (Ausubel
et al., 1998). Among such glycoproteins are proteogly-
cans which have long linear GAG chains comprising
repeating disaccharides; most are membrane associ-
ated or bound to the extracellular matrix, have variable
degrees of sulfation, and have a high density of neg-
FIG. 2. Immunoprecipitation of the 30-kDa protein from 14C/35S-la-
beled SCP membrane lysates. Cell fractions were prepared as de-
scribed under Materials and Methods. M represents the membrane
fraction (lanes 1 and 2), C represents the cytoskeletal aggregate frac-
tion (lanes 3 and 4), and H is the homogenate fraction (lanes 5 and 6).
Equal amounts of protein solubilized from each 14C/35S-labeled fraction
were subjected to immunoprecipitation with NRS (2) (lanes 1, 3, and 5)
or 2-23 (1) (lanes 2, 4, and 6). Immune complexes were resolved by
SDS–PAGE (12%) and processed for autoradiography. The arrow indi-
cates the location of the 30-kDa protein.
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135VISNA VIRUS MEMBRANE-ASSOCIATED PROTEINative charge. Chondroitin sulfate/dermatan sulfate,
heparan sulfate/heparin, and keratan sulfate are the
three classes of GAGs that are found attached to
proteoglycans. Because glycoproteins such as proteo-
glycans resist staining by standard methods, alternate
methods are often used, such as the carbohydrate-
specific periodic acid Schiff (PAS) staining (Fukuda
and Kobata, 1993). If used before silver staining, PAS
augments the silver reaction for glycoproteins. In light
of the possibility that the 30-kDa protein is glycosy-
lated, proteins immunoprecipitated by 2-23 were sep-
arated by SDS–PAGE and stained with PAS followed by
silver staining. Because this method enabled visual-
ization of the 30-kDa protein in the gel (not shown), we
concluded that the protein was likely glycosylated.
To further examine the 30-kDa protein, experiments
were designed to examine the presence of sugar sub-
stituents. 35S-labeled samples immunoprecipitated
ith 2-23 were treated with enzymes that cleave spe-
ific sugars from glycoproteins and proteoglycans.
eptide N-glycosidase F (PNGaseF) cleaves N-linked
ugars from their core proteins (Elder and Alexander,
982). Polysaccharide lyases recognize and cleave the
AG chains from proteoglycans in a specific manner
Linhardt et al., 1986). Heparin lyase I (heparinase I)
leaves heparin, heparin lyase III (heparinase III)
leaves heparan sulfate, chondroitin ABC lyase (chon-
roitinase ABC) cleaves both chondroitin sulfate and
ermatan sulfate, and chondroitin AC lyase (chon-
roitinase AC) cleaves only chondroitin sulfate chains
rom core proteins (Linhardt et al., 1986). Immune
omplexes of 2-23 from 35S-labeled FLK-BLV lysates
were subjected to overnight digestion by each of the
enzymes prior to separation by SDS–PAGE on a 12%
gel (Fig. 3). Lanes 1 and 2 of Fig. 3 represent “untreat-
ed” immunoprecipitations with 2-23 and NRS per-
formed exactly as in Figs. 1 and 2. As a control for the
digestion conditions, “Mock”-digested samples of im-
munoprecipitates with 2-23 or NRS were incubated in
digestion buffer without enzyme overnight and treated
in the same manner as the digested samples (Fig. 3,
lanes 3 and 9). Immunoprecipitations treated with PN-
GaseF, heparinase I, and heparinase III did not shift
the apparent molecular weight of the 30-kDa protein
compared to the mock-treated sample (compare Fig. 3,
lanes 4, 5, and 6 with lane 3). Note that mock-treated
samples are incubated in enzymatic buffers lacking
only the enzymes. In contrast, a shift to a lower ap-
parent molecular weight of the 30-kDa protein com-
pared to the mock-treated immunoprecipitation was
observed with both chondroitinase ABC and chon-
droitinase AC, indicating the presence of a chondroitin
sulfate chain(s) on the 30-kDa protein (compare Fig. 3,
lanes 7 and 8 with lane 3). a4-Methylumbelliferyl-b-D-xyloside, an inhibitor of
roteoglycan synthesis, also reduces
isna virus replication
To investigate the role of GAG chains in visna virus
inding and infection of target cells, addition of GAG
hains to proteoglycans in SCP cells was inhibited with
b-D-xyloside prior to infection, a technique used in
many previous reports (Gibson and Segen, 1977; Gibson
et al., 1977; Okayama et al., 1973). At low concentrations
in the mM range) these hydrophobic xylosides penetrate
he cell membrane and target the Golgi apparatus, where
hey are added to the carbohydrate core. The xyloside
-methylumbelliferyl-b-D-xyloside (Xylb4MU) competes
with endogenous proteoglycan core proteins and acts as
a GAG acceptor (Freeze et al., 1993). This competition
results in the increased secretion of protein-free GAG
chains and decreased production of intact proteoglycan
monomers. Proteoglycans synthesized in the presence
of xylosides usually display decreased GAG chain
length, fewer GAG chains, and variable degrees of sul-
fation (Gibson and Segen, 1977; Murray et al., 1983). The
xyloside primes chondroitin sulfate efficiently and hepa-
ran sulfate only weakly. Treatment of SCP cells with 1
mM Xylb4MU prior to infection resulted in a marked
eduction in virus-induced cell fusion and virus produc-
ion, as measured by a standard reverse transcriptase
ssay (Fig. 4).
he 30-kDa protein can be immunoprecipitated from
rimary sheep cells
FIG. 3. Enzymatic deglycosylation of immunoprecipitated proteins.
35S-labeled FLK-BLV cell lysates (500 mg) were immunoprecipitated and
reated with enzymes that cleave specific sugar entities from the core
roteins. Untreated NRS (lane 1) and 2-23 (lane 2) immunoprecipita-
ions were performed as in Fig. 1. Mock treatments of 2-23 (lane 3) and
RS (lane 9) immunoprecipitations were incubated with digestion
uffer only, under the same conditions as those reactions containing
nzyme. Lanes 4 through 8 are immunoprecipitations treated with
pecific glycosidases. PNGaseF, 1.2 U (lane 4); heparinase I (HI), 50 U
lane 5); heparinase III (HIII), 50 U (lane 6); chondroitinase ABC (C-ABC),
0 U (lane 7); and chondroitinase AC (C-AC), 40 U (lane 8). Proteins
ere analyzed on a 12% SDS gel and detected by autoradiography.Because the cumulative data presented above support
role for a 30-kDa membrane-associated chondroitin
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136 BRUETT, BARBER, AND CLEMENTSsulfate proteoglycan, we next examined the ability of
2-23 to immunoprecipitate the 30-kDa protein from 35S-
labeled primary sheep brain microvascular endothelial
cells (SBEC) and sheep adipose endothelial cells
(SAEC). We have previously reported the ability of both
primary cell types to support visna virus replication
(Craig et al., 1997). The results indicate the presence of
the 30-kDa protein in 2-23 immunoprecipitates from both
brain and adipose endothelial cells (Fig. 5, lanes 2 and
4). Relevantly, the 30-kDa protein was also immunopre-
cipitated by 2-23 from 35S-labeled primary sheep macro-
phages, which represent the major target cells for visna
virus replication in vivo (not shown).
FIG. 4. Visna virus infection of SCP cells treated with the glycosamin
or without 1 mM Xylb4MU and infected in the same medium for 5 day
Methods. Supernatants were collected 5 days after infection and subje
plotted. Each treatment was done in triplicate, and error bars indicate
FIG. 5. SAEC and SBEC 35S-labeled lysates (350 mg) were immuno-
precipitated with 2-23 (1) or Pre 2-23 (2). SAEC and SBEC cells are
each primary sheep cells susceptible to visna virus infection. ImmuneF
o
complexes were analyzed on 12% SDS–PAGE and processed as in Fig.
1. The arrow indicates the location of the 30-kDa protein.DISCUSSION
The cellular receptors for visna virus and the other
ovine and caprine lentiviruses are currently unknown,
although two previous reports have implicated, indepen-
dently, the involvement of a 30-kDa membrane protein in
the binding of visna virus to susceptible cells (Crane et
al., 1991; Dalziel et al., 1991). In addition to the 30-kDa
protein, our laboratory identified two other membrane
proteins (45 and 15 kDa) from visna virus-susceptible
cells that bound the virus in a VOPBA (Crane et al., 1991).
Polyclonal antiserum was raised to each protein, but only
polyclonal antiserum (2-23) to the 45-kDa protein specif-
ically labeled the surfaces of SCP cells and blocked
visna virus binding to SCP cells. Surprisingly, 2-23 rec-
ognized not only the immunogen (45-kDa protein) but
also the 30-kDa protein in Western analysis of SCP
membranes. In the present study, 2-23 significantly re-
duced the infection of susceptible cells and immunopre-
cipitated a putative complex of two proteins (30 and 45
kDa). We found the 30-kDa protein to be the most prom-
inent in the 2-23 immunoprecipitations from both 14C and
35S-labeled cell lysates, possibly indicating that the 30-
Da protein is more abundant in cells or that this protein
ad a higher turnover rate in the cell. This disproportion-
te incorporation of both radiolabels into the 30- and
5-kDa proteins suggests that it is unlikely that the 30-
Da protein represents either a proteolytically processed
orm of the 45-kDa protein or a precursor for the 45-kDa
rotein, rather it reflects the stoichiometry of the com-
lex. Biochemical analyses suggested that the 30-kDa
rotein is modified with a chondroitin sulfate GAG chain.
n synthesis inhibitor Xylb4MU. SCP cells were grown in medium with
3 104 TCID50/ml visna virus 1514, as described under Materials and
a standard reverse transcriptase assay; counts per minute (cpm) were
ndard deviation.oglyca
s with 1urther, we found that the GAG chains are important for
ptimal efficient visna virus infection.
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137VISNA VIRUS MEMBRANE-ASSOCIATED PROTEINAnalysis of the 30-kDa protein using various polysac-
charide lyases demonstrated sensitivities to chondroiti-
nase ABC (C-ABC) and chondroitinase AC (C-AC) as
evidenced by the emergence of a faster migrating pro-
tein, consistent with the decrease in molecular weight
expected as polysaccharides are cleaved. Although a
slightly shifted band is present in the PNGaseF, hepari-
nase I, and heparinase III digestions, the same smaller
band is also present in the mock 2-23 immunoprecipita-
tion and likely results from protein degradation due to
digestion conditions and overnight incubation at 37°C.
Since C-AC cleaves only chondroitin sulfate, the sub-
stantial shift in molecular weight provides evidence that
the 30-kDa band is substituted with a chondroitin sulfate.
The concomitant shift in molecular weight observed with
C-ABC, which cleaves both chondroitin and dermatan
sulfates, supports the chondroitin sulfate composition of
the 30-kDa protein, as an even lower species would be
expected to emerge if two sugars were cleaved. How-
ever, since a dermatan sulfate-specific lyase was not
utilized, it cannot be ruled out that the single lower band
emerging after C-ABC treatment may contain a hetero-
geneous population of singly and/or doubly cleaved 30-
kDa proteins that share a common migration position in
SDS–PAGE. Indeed, the shift in molecular weight is rel-
atively small, which may suggest that there are only a
few GAG chains on the core protein or that the sugar
chain is very small. In any case, it is quite clear that the
30-kDa protein is a small proteoglycan substituted with
chondroitin sulfate (GAG) chains. Precedent for the use
of proteoglycans as viral receptors already exists. For
example, foot and mouth disease type O virus, HSV types
1 and 2, dengue virus, AAV-2, and pseudorabies virus all
use proteoglycans as their cellular receptors (Banfield et
al., 1995; Chen et al., 1997; Immergluck et al., 1998;
Jackson et al., 1996; Karger and Mettenleiter, 1996; Shieh
t al., 1992; Spear et al., 1992; Summerford and Samulski,
998).
The importance of GAG chains to visna virus infection
s further supported by the results obtained using the
b-D-xyloside, Xylb4MU, a preferential inhibitor of chon-
roitin sulfate addition to proteoglycans, which substan-
ially inhibited visna virus infection of SCP cells. Because
he effect of Xylb4MU is not specific for the 30-kDa
protein, the interpretation of these results simply sup-
ports a role in vivo for proteoglycans in visna virus
eplication. In addition to serving as bonafide virus re-
eptors (above) glycosaminoglycan chains which project
ong, charged regions from the cell surface may serve to
ind the virus loosely to the extracellular millieu thereby
acilitating recognition of the functional virus receptor(s).
s one parallel example, proteoglycans have been
hown to sequester serum proteins such as chemokines
nd present them to the appropriate chemokine receptorHoogewerf et al., 1997). Another example, depicting how
iruses may have evolved to capitalize on such cooper-tivity, is illustrated by HSV-1, which has been shown to
ind a cell surface heparan sulfate prior to binding its
ognate receptor (WuDunn and Spear, 1989). Perhaps
ven more relevant to visna virus, recent reports impli-
ate cell surface heparan sulfate proteoglycans in HIV-1
nfection (Ohshiro et al., 1996; Patel et al., 1993; Rode-
iquez et al., 1995).
These studies have shown that a complex of two
ellular proteins is recognized by antiserum that specif-
cally blocks visna virus binding and inhibits virus infec-
ion and that the 30-kDa protein appears to be the most
rominent protein in the labeled complex. This 30-kDa
rotein is membrane associated and is a chondroitin
ulfate proteoglycan that may serve as a visna virus
eceptor. Future studies will address the role and identity
f this proteoglycan in relation to other proteins compris-
ng the complex involved in visna virus cell binding and
nfection.
MATERIALS AND METHODS
eagents
C-ABC from Proteus vulgaris and C-AC, heparinase I,
and heparinase III, all from Flavobacteium heparinum;
Xylb4MU; and minimum essential medium (Eagle’s) with-
out methionine (EMEM-met) were obtained from Sigma
(St. Louis, MO). Minimum essential medium with Earle’s
salts (EMEM), Dulbecco’s modified eagle medium
(DMEM), Hanks’ balanced salt solution (HBSS), and
MEM Select-Amine kit (14C labeling medium and 14C/35S
labeling medium) were obtained from GIBCO BRL (Gaith-
ersburg, MD). 14C labeling medium was prepared follow-
ng the manufacturer’s instructions for the MEM Select-
mine kit supplemented with only L-tryptophan, L-glu-
tamine, L-methionine, and L-cystine. 14C/35S labeling
edium was prepared from the MEM Select-Amine kit
upplemented with only L-tryptophan and L-glutamine.
Fetal bovine serum (FBS) was obtained from Atlanta
Biologicals (Norcross, GA).
Cells and viruses
SCP cells were obtained as previously described
(Narayan et al., 1977, 1978, 1980). GSM cells were iso-
lated in our lab as previously described (Narayan et al.,
1980). FLK-BLV cells were obtained from Dr. David Derse
(NCI, Frederick, MD); MDOK cells, NIH-3T3 cells, and
QT6 cells were obtained from the ATCC (Manassas, VA).
SBEC and SAEC were isolated in our laboratory as de-
scribed (Craig et al., 1998). All cells were cultured at
37°C with 5% CO2. SCP, FLK-BLV, and GSM cells were
cultured in EMEM supplemented with 10% FBS, MDOK
cells were cultured in EMEM supplemented with 10%
lamb serum, and NIH-3T3 cells and QT6 cells were
cultured in DMEM supplemented with 10% FBS. The
SBEC and SAEC were grown in complete endothelial cell
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138 BRUETT, BARBER, AND CLEMENTSmedium as described (Craig et al., 1998). Visna virus
strain 1514 was prepared as previously described (Cork
et al., 1974; Narayan et al., 1978; Pyper et al., 1984).
Antisera
Rabbit polyclonal antiserum 2-23 was raised against a
cellular membrane protein of ;45 kDa previously shown
to bind visna virus (Crane et al., 1991). Serum controls
included preimmune serum collected from the 2-23 rab-
bit (Pre 2-23) and NRS obtained from Jackson Immu-
noResearch Laboratories, Inc. (Westgrove, PA). Goat
polyclonal antiserum (NN) was raised against whole
visna virus. This antiserum neutralizes visna virus in the
standard neutralization assay below. ChromPure Rabbit
IgG (commercially pure normal rabbit IgG) was obtained
from Jackson ImmunoResearch Laboratories, Inc. IgG
was purified from rabbit polyclonal antiserum 2-23, nor-
mal rabbit serum, and NN neutralizing serum using the
MAbTrapGII affinity purification kit (Pharmacia, Piscat-
away, NJ). The protein concentration of the purified IgG
was measured using the Bradford-based Bio-Rad protein
assay, microassay procedure (Bio-Rad, Hercules, CA).
Virus infectivity assay
Confluent monolayers of SCP cells cultured in 48-well
dishes were incubated in EMEM 1 0.5% FBS, with 300
mg/ml IgG purified from 2-23 serum, with IgG purified
from NRS (described above), or with commercially puri-
fied normal rabbit IgG, for 4 h at 4°C. Visna virus (100
CID50/well) was added to the cells in medium contain-
ing the various IgGs and incubated at 4°C. After 4 h, the
cells were washed three times with EMEM 1 0.5% FBS
and the appropriate IgG treatment was added in
EMEM 1 0.5% FBS. The infected cells were incubated at
7°C for 7 days, after which the supernatant was re-
oved, virus was quantitated by limiting dilution, and
CID50 was calculated by the method of Karber (1931).
odified neutralization assay
In a standard neutralization assay visna virus (100
CID50/100 ml) is preincubated with dilutions of neutral-
izing antibody in EMEM 1 0.5% FBS for 1 h at 37°C. Virus
and antibody are then added to confluent monolayers of
SCP cells in 96-well plates. The negative control is virus
preincubated with medium without antiserum or with
preimmune serum and is processed the same as above.
Virus cytopathic effects (cpe) are recorded at 7 days
postinoculation (p.i.) and neutralization dose is calcu-
lated by the method of Karber (1931). To determine
whether the 2-23 antiserum had any neutralizing effect
on the virus, this standard assay was modified as fol-
lows. Virus and antibody (2-23 IgG and normal rabbit IgG
at 300 mg/ml and NN at 1 to 50 dilution) were incubated
or 1 h at 37°C after which virus was pelleted through a
ushion of 20% sucrose/Tris 25 mM, pH 8.0, NaCl 150 aM, EDTA 2 mM in a Sorvall 5CRC high-speed centri-
uge with the SH-MT rotor at 13,500 rpm to remove free
nbound antibody. The virus pellet was resuspended in
00 ml of EMEM 1 0.5% FBS and used to infect SCP cells
as described above. Virus cpe were evaluated 7 days p.i.
Metabolic labeling of cells
Cells (;1.0 3 107) were washed twice with HBSS,
tarved in 14C-labeling medium for 1 h at 37°C, and
labeled overnight at 37°C in 14C-labeling medium sup-
lemented with 1% FBS and 10 mCi/ml L-[U-14C]amino
acid mixture from NEN Life Science Products, Inc. (Bos-
ton, MA). For double-labeling experiments with both
Tran35S-Label (ICN Pharmaceuticals, Irvine, CA) and
14C]amino acids (referred to as 14C/35S labeled), ;2.0 3
07 cells were starved in 14C/35S labeling medium for 1 h
and incubated overnight at 37°C in the same medium
supplemented with 1% FBS, 70 mCi/ml Tran35S-Label,
and 10 mCi/ml L-[U-14C]amino acids. 35S-labeled cells
(;1.0 3 107) were starved in EMEM-met for 1 h at 37°C
nd labeled for 5 h at 37°C in EMEM-met supplemented
ith 1% FBS and 70–150 mCi/ml Tran35S-Label (referred
o as 35S-labeled throughout).
mmunoprecipitation
Radiolabeled cells were washed three times with
BSS and lysed on ice for 1 h in lysis buffer [6.5 mM
HAPS, 50 mM Tris–HCl, pH 7.5, 0.15 M NaCl, containing
omplete protease inhibitor cocktail (Boehringer Mann-
eim, Indianapolis, IN)]. Lysates were clarified by cen-
rifugation for 10 min at 12,000 rpm, and the supernatant
as assayed for total protein concentration using the
radford-based Bio-Rad protein assay, microassay pro-
edure (Bio-Rad). Immunoprecipitations from 0.1 to 0.5
g of protein were performed overnight with either 2-23,
re 2-23, or the normal rabbit serum control. Following
ncubation with protein G–Sepharose beads (Amersham,
rlington Heights, IL), immune complexes were pelleted
1 min at 12,000 rpm), washed three times with lysis
uffer, washed once with lysis buffer without CHAPS,
nd finally resuspended in 23 solubilization buffer
Laemmli, 1970). Following resolution by SDS–PAGE,
els were fixed for 1.5 h (20% isopropanol, 10% glacial
cetic acid), rinsed in dH2O, and soaked for 30 min in 1
M salicylic acid, sodium salt (Aldrich Chemical Co., Mil-
waukee, WI), prior to being dried and processed for
autoradiography using either Kodak X-OMAT blue or
Kodak MR film (Kodak, Rochester, NY). Films were
scanned using the UMAX Powerlook II scanner into
Adobe PhotoShop 5.0, and figures were assembled us-
ing Adobe Illustrator 8.0.
Preparation of cell membrane fractions
8 14 35SCP cells (;2 3 10 , C/ S labeled, as described
bove) were washed three times in ice-cold PBS and
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139VISNA VIRUS MEMBRANE-ASSOCIATED PROTEINincubated (at 4°C) in PBS containing 1 mM EDTA until
the adherent cells could be released by slapping the
sides of the flasks. Released cells (.95%, as assessed
microscopically) were pelleted (2000 rpm, 4°C, 8 min)
and resuspended in 7 ml of ice-cold homogenization
buffer (25 mM HEPES, pH 7.3; 0.5 mM EGTA; 0.5 mM
sodium orthovanadate; 0.1 mM sodium molybdate; 1 mM
sodium fluoride) containing protease inhibitors (2 Com-
plete tablets/50 ml; Boehringer Mannheim, Mannheim,
Germany). Cell lysates were prepared by dounce homog-
enization (100 strokes) essentially as described previ-
ously (Bhat et al., 1999). Low-speed centrifugation
1000g, 10 min, 4°C) of homogenates was performed to
remove unlysed cells, nuclei, and cell fragments (Jesaitis
et al., 1982). The resulting supernatant was subjected to
high-speed centrifugation (10,000 rpm, 7 min, 4°C) to
pellet cytoskeletal aggregates (Sambrook et al., 1971).
Pellets (representing cytoskeletal aggregates) were in-
cubated on ice while the supernatants were subjected to
centrifugation (417,000g, 2 h, 4°C) in order to pellet cell
membranes. Resulting supernatants were designated
“homogenates” (;7 ml), decanted into tubes, and incu-
bated on ice. Residual supernatant was removed from
the ultracentrifuge tubes containing visible membrane
pellets using cotton-tipped applicators. Proteins were
solubilized from membrane pellets (M) and cytoskeletal
aggregates (C) in 3 ml of homogenization buffer supple-
mented with 10 mM CHAPS (overnight, 4°C). Accord-
ingly, the homogenate fraction designated H (represent-
ing the supernatant following ultracentrifugation) was
supplemented with CHAPS (to achieve a final concen-
tration of 10 mM) and processed as described above.
Proteins from each fraction were concentrated using
Centricon3 protein concentrators (above) and equal
amounts of protein (derived from each fraction) were
used in immunoprecipitation assays.
Glycosidase and polysaccharide lyase treatment of
immunoprecipitations
35S-labeled immunoprecipitations (from 500 mg lysate)
ere prepared from FLK-BLV cells as described above.
ollowing the final wash in lysis buffer without CHAPS,
mmune complexes were resuspended in 50 ml of the
ppropriate buffer containing 50 mU heparinase I, 50 mU
eparinase III, 40 mU chondroitinase ABC, or 40 mU
hondroitinase AC (units represent “Sigma units”). Buff-
rs for the lyases were 50 mM sodium phosphate with
00 mM NaCl, pH 7.1 (heparinase I); 50 mM sodium
hosphate, pH 7.6 (heparinase III); and 50 mM Tris, with
0 mM sodium acetate, pH 8.0 (chondroitinase ABC and
hondroitinase AC). Overnight digestions with hepari-
ase I, chondroitinase ABC, and chondroitinase AC were
ncubated at 37°C, while heparinase III digestions were
ncubated at 30°C. Digestion with PNGaseF was per-
ormed essentially according to the manufacturer’s spec-fications, using the N-Glycosidase F Deglycosylation Kit
rom Boehringer Mannheim. Briefly, immune complexes
ere resuspended in 5 ml of denaturation buffer and 5 ml
f water and heated at 95°C for 3 min. Reaction buffer (10
ml) and N-glycosidase F (1.2 U) were then added, and the
digestions were incubated overnight at 37°C. Enzyme-
treated immune complexes were resolved by 12% SDS–
PAGE as described above. “Mock” immunoprecipitates
were incubated in the appropriate enzyme-specific buffer
in the absence of enzyme and processed identically.
“Untreated” immunoprecipitates were processed exactly
as described under “Immunoprecipitation” above.
Inhibition of proteoglycan synthesis
SCP cells were grown to confluence in the presence of
EMEM 1 10% FBS or in EMEM 1 10% FBS supple-
mented with 1 mM Xylb4MU. Cells were washed twice
ith HBSS, after which the medium was changed to
MEM 1 0.5% FBS with or without 1 mM Xylb4MU, and
cells were infected with 1 3 104 TCID50/ml visna virus for
h at 37°C. Cells were washed twice with EMEM 1 0.5%
BS, and the medium was replaced with either EMEM 1
.5% FBS or medium supplemented with 1 mM Xylb4MU.
upernatants collected 5 days after infection were as-
ayed for virus production by reverse transcriptase ac-
ivity (Clabough et al., 1991).
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